ArticleBMJ case reports2019
Chylothorax: complication attributed to dasatinib use.
Article in BMJ case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- Dasatinib-Associated Chylothorax: A Scoping Review and Pharmacovigilance Analysis.Therapeutic innovation & regulatory science · 2026Article
- Adverse Respiratory Reactions to Tyrosine Kinase Inhibitors: A Disproportionality Analysis of Spontaneous Reports from European Countries.Life (Basel, Switzerland) · 2026Article
- Case Report: Dasatinib-associated chylothorax and occultFrontiers in pharmacology · 2026Article
- Review
- Clinical characteristics and management of dasatinib-induced chylothorax: retrospective analysis based on case reports.Frontiers in pharmacology · 2025Article
- Drug-Induced Chylothorax During Chemotherapy With Ramucirumab and Paclitaxel for Advanced Gastric Cancer.Cureus · 2025Article
- Article
- Dasatinib-associated chylothorax in a pediatric patient with chronic myeloid leukemia: a case report and literature review.Translational cancer research · 2023Article
- Dasatinib-Induced Chylothorax Beyond 5 Years of Treatment: Is There Actually Any Limit?European journal of case reports in internal medicine · 2023Article
- Diagnostic Pitfalls of Chylothorax After Dasatinib Treatment of Chronic Myeloid Leukemia.The American journal of case reports · 2022Article
- Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2022Article
- Article
- A Dasatinib-Induced Chylothorax Persisting After the Discontinuation of Dasatinib.European journal of case reports in internal medicine · 2022Article
- Dasatinib-induced chylothorax in a patient with chronic myeloid leukaemia: a case report and literature review.Respirology case reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 63-year-old woman with a medical history of chronic myelogenous leukaemia treated with dasatinib, chronic obstructive pulmonary disease and heart failure with preserved ejection fraction presented with difficulty in breathing. Chest X-ray showed large right-sided pleural effusion, which was confirmed on a CT angiogram of the chest. Echocardiogram showed an ejection fraction of 61% with moderate to severely dilated right ventricle and right ventricular systolic pressure of 60 mm Hg. Diagnostic and therapeutic thoracentesis was performed, and 2.2 L of pleural fluid was removed. Pleural fluid analysis was consistent with chylothorax. Significant symptomatic improvement was noted after thoracentesis. In the absence of an alternate explanation, chylothorax was attributed to dasatinib, which was switched to nilotinib. This resulted in resolution of her pleural effusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.